Evidence map›Paper›PMID 41951100›Full record

ArticleMucosal immunology2026

Differential effects of SARS-CoV-2-targeted infection of ATII, club cells, and macrophages on lung immunopathology and antiviral responses.

Austin W Todd, Sergey A Shein, Anna A Korchagina, Vasily A Kudinov, Brianna N Faz, Ramya S Barre, Raehum Paik, Emma C Collins, Kizil A Yusoof, Ishana Khetarpal and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mucosal immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Austin W ToddDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), TX 78229, USA.
Sergey A SheinDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), TX 78229, USA.
Anna A KorchaginaDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), TX 78229, USA.
Vasily A KudinovDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), TX 78229, USA.
Brianna N FazDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), TX 78229, USA.
Ramya S BarreTexas Biomedical Research Institute, San Antonio, TX, USA.
Raehum PaikDepartment of Cellular and Integrative Physiology, UTHSCSA, TX, USA.
Emma C CollinsDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), TX 78229, USA.
Kizil A YusoofDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), TX 78229, USA.
Ishana KhetarpalDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), TX 78229, USA.
Korri S WeldonGreehey Children's Cancer Institute, UTHSCSA, TX, USA.
Zhao LaiGreehey Children's Cancer Institute, UTHSCSA, TX, USA; Department of Molecular Medicine, UTHSCSA, TX, USA.
Dias KurmashevGreehey Children's Cancer Institute, UTHSCSA, TX, USA.
Jordi B TorrellesTexas Biomedical Research Institute, San Antonio, TX, USA.
Elizabeth A LeadbetterDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), TX 78229, USA.
Yan XiangDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), TX 78229, USA.
Yidong ChenGreehey Children's Cancer Institute, UTHSCSA, TX, USA.
Luis Martinez-SobridoTexas Biomedical Research Institute, San Antonio, TX, USA.
Ekaterina KorolevaDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), TX 78229, USA.
Alexei V TumanovDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), TX 78229, USA. Electronic address: tumanov@uthscsa.edu.

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Lymphotoxin-Beta Receptor Peripheral Signaling Regulates the Transition to Inflammation and Neuropathy-Induced Chronic PainR01NS112263 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI AKOPIAN, ARMEN N, TUMANOV, ALEXEI V · 2020 to 2024
$2.4M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM145432 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jose E Cavazos, Ratna K Vadlamudi · 2023 to 2026
$2.3M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM113896 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CAVAZOS, JOSE E · 2018 to 2022
$1.1M
Advancing Cancer Research Through Next Generation Sequencing at Mays Cancer Center of UT Health San AntonioR50CA265339 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Zhao Lai · 2022 to 2026
$957k
Illumina NovaSeq 6000 Sequencing SystemS10OD030311 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2021 to 2021
$600k
FACSAria Fusion cell sorter for Flow Cytometry Shared ResourceS10OD030432 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BERTON, MICHAEL T · 2022 to 2022
$596k
Novel animal models to study organ-specific SARS-CoV-2-induced pathologyR21AI173816 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KOROLEVA, EKATERINA, MARTINEZ-SOBRIDO, LUIS · 2023 to 2024
$499k
Animal models of SARS-CoV-2 bacterial CoinfectionR21AI166575 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI XIANG, YAN · 2022 to 2023
$426k
Dissecting the mechanism of altered immune responses during obesityR21AI183125 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KOROLEVA, EKATERINA, LEADBETTER, ELIZABETH ANN · 2025 to 2025
$426k
Targeting SARS-CoV-2 induced lung immunopathology using novel genetic mouse modelsR21AI161400 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KOROLEVA, EKATERINA, TUMANOV, ALEXEI V · 2022 to 2023
$419k
Lymphotoxin-dependent control of long COVIDR21AI185790 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Alexei V Tumanov · 2026 to 2026
$235k
NCI NIH HHS P30 CA054174NCI NIH HHS R50 CA265339NIAID NIH HHS R21 AI161400NIAID NIH HHS R21 AI166575NIAID NIH HHS R21 AI173816NIAID NIH HHS R21 AI183125NIAID NIH HHS R21 AI185790NIGMS NIH HHS T32 GM113896NIGMS NIH HHS T32 GM145432NIH HHS S10 OD030311NIH HHS S10 OD030432NINDS NIH HHS R01 NS112263
6 · The paper itself

Abstract

The specific contributions of lung epithelial and immune cells to SARS-CoV-2-induced immunopathology and antiviral responses remain unclear. To address this, we generated mouse models with inducible expression of human angiotensin-converting enzyme 2 (hACE2) in specific lung cell types. Infection of mice expressing hACE2 on club cells triggered early type I interferon responses, limited viral replication, and caused transient, mild lung pathology. In contrast, hACE2-driven infection of type II alveolar epithelial cells (ATIIs) resulted in higher viral loads and moderate lung damage, accompanied by expansion of interstitial macrophages, virus-specific CD8

Indexed as

Alveolar Epithelial CellsAngiotensin-Converting Enzyme 2COVID-19LungMacrophagesSARS-CoV-2AnimalsCD8-Positive T-LymphocytesChemokine CXCL10Chemokine CXCL9Disease Models, AnimalHumansMacrophages, AlveolarMiceMice, Inbred C57BLMice, TransgenicACE2 protein, humanAce2 protein, mouseAngiotensin-Converting Enzyme 2Chemokine CXCL10Chemokine CXCL9ACE2Club cellsMacrophagesMouse models of SARS-CoV-2 diseaseSARS-CoV-2Type II alveolar epithelial cells

Identifiers

PMID41951100
PMCPMC13296609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.